Alternative coagulation promoters and gene therapies to drive hemophil - The Pharma Letter

Alternative coagulation promoters and gene therapies to drive hemophil  The Pharma Letter

Replacement factors are the current standard-of-care for both hemophilia A and B, representing 97% of the total sales of the hemophilia market in 2018.